Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer

被引:51
作者
Bollschweiler, Elfriede [1 ]
Hoelscher, Arnulf H. [1 ]
Metzger, Ralf [1 ,2 ]
机构
[1] Univ Cologne, Dept Gen Visceral & Canc Surg, D-50937 Cologne, Germany
[2] Univ Hosp Cologne, CIO, Cologne, Germany
关键词
adenocarcinomo; esophagus; neoadjuvant chemoradiation; pathologic complete response; regression grading; squamous cell carcinoma; SQUAMOUS-CELL CARCINOMA; RANDOMIZED CONTROLLED-TRIALS; RADIATION-THERAPY; CHEMORADIATION THERAPY; PHASE-II; PREOPERATIVE CHEMORADIOTHERAPY; GASTROESOPHAGEAL JUNCTION; PATHOLOGICAL RESPONSE; ENDOSCOPIC ULTRASOUND; RESECTABLE CANCER;
D O I
10.2217/FON.09.133
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A review of the literature demonstrated that clinical evaluation cannot be used to determine 'complete response'. The different classification systems of the histopathologic response grading after neoadjuvant radiochemotherapy of esophageal carcinoma are summarized in this report. A systematic review of studies analyzing preoperative chemoradiation of squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the esophagus demonstrated no significant difference in pathologic complete response (pCR) rates between the AC and SCC studies. Analyzing only the applied dose of radiation demonstrated that patients with AC required a higher dose than patients with SCC to achieve complete response. Incorporating chemotherapy administration does not markedly change the difference in required radiation dose. However, when the tumor does respond, the rate of pCR with increasing dosage of chemoradiotherapy increases more rapidly in AC patients than in SCC patients.
引用
收藏
页码:25 / 35
页数:11
相关论文
共 69 条
[1]  
Adelstein DJ, 1997, CANCER-AM CANCER SOC, V80, P1011
[2]  
Adham M, 2000, CANCER, V89, P946
[3]  
Ajani JA, 2001, CANCER-AM CANCER SOC, V92, P279, DOI 10.1002/1097-0142(20010715)92:2<279::AID-CNCR1320>3.0.CO
[4]  
2-2
[5]   Clinical and Pathologic Evaluation of the Effectiveness of Neoadjuvant Chemoradiation Therapy in Advanced Esophageal Cancer Patients [J].
Akutsu, Yasunori ;
Matsubara, Hisahiro ;
Shuto, Kiyohiko ;
Uesato, Masaya ;
Mori, Mikito ;
Hoshino, Isamu ;
Shiratori, Toru ;
Miyazawa, Yukimasa ;
Ito, Hisao ;
Uno, Takashi .
WORLD JOURNAL OF SURGERY, 2009, 33 (05) :1002-1009
[6]  
APINOP C, 1994, HEPATO-GASTROENTEROL, V41, P391
[7]   Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: Criteria of the histopathological evaluation [J].
Baldus S.E. ;
Mönig S.P. ;
Schröder W. ;
Metzger R. ;
Lang S. ;
Zirbes T.K. ;
Thiele J. ;
Müller R.P. ;
Dienes H.P. ;
Hölscher A.H. ;
Schneider P.M. .
Der Pathologe, 2004, 25 (6) :421-427
[8]   Refining esophageal cancer staging after neoadjuvant therapy: Importance of treatment response [J].
Barbour, Andrew P. ;
Jones, Mark ;
Gonen, Mithat ;
Gotley, David C. ;
Thomas, Janine ;
Thomson, Damien B. ;
Burmeister, Bryan ;
Smithers, B. Mark .
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (10) :2894-2902
[9]   Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma [J].
Bates, BA ;
Detterbeck, FC ;
Bernard, SA ;
Qaqish, BF ;
Tepper, JE .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :156-163
[10]   Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy [J].
Becker, K ;
Mueller, JD ;
Schulmacher, C ;
Ott, K ;
Fink, U ;
Busch, R ;
Böttcher, K ;
Siewert, JR ;
Höfler, H .
CANCER, 2003, 98 (07) :1521-1530